Literature DB >> 28246436

Mepolizumab.

.   

Abstract

Entities:  

Year:  2017        PMID： 28246436      PMCID： PMC5313247          DOI： 10.18773/austprescr.2016.092

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  5 in total

1.  Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis.

Authors:  Pranabashis Haldar; Christopher E Brightling; Amisha Singapuri; Beverley Hargadon; Sumit Gupta; William Monteiro; Peter Bradding; Ruth H Green; Andrew J Wardlaw; Hector Ortega; Ian D Pavord
Journal:  J Allergy Clin Immunol       Date:  2014-01-10       Impact factor: 10.793

Review 2.  Mepolizumab versus placebo for asthma.

Authors:  Colin Powell; Stephen J Milan; Kerry Dwan; Lynne Bax; Nicola Walters
Journal:  Cochrane Database Syst Rev       Date:  2015-07-27

3.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.

Authors:  Ian D Pavord; Stephanie Korn; Peter Howarth; Eugene R Bleecker; Roland Buhl; Oliver N Keene; Hector Ortega; Pascal Chanez
Journal:  Lancet       Date:  2012-08-18       Impact factor: 79.321

4.  Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.

Authors:  Elisabeth H Bel; Sally E Wenzel; Philip J Thompson; Charlene M Prazma; Oliver N Keene; Steven W Yancey; Hector G Ortega; Ian D Pavord
Journal:  N Engl J Med       Date:  2014-09-08       Impact factor: 91.245

5.  Mepolizumab treatment in patients with severe eosinophilic asthma.

Authors:  Hector G Ortega; Mark C Liu; Ian D Pavord; Guy G Brusselle; J Mark FitzGerald; Alfredo Chetta; Marc Humbert; Lynn E Katz; Oliver N Keene; Steven W Yancey; Pascal Chanez
Journal:  N Engl J Med       Date:  2014-09-08       Impact factor: 91.245
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.